Hormonal
Tirzepatide use is associated with a significantly lower risk of suicidal ideation or suicide attempts compared to other anti-obesity medications in a real-world cohort.
Current real-world evidence suggests that tirzepatide is not associated with an increased risk of suicide and may be associated with a lower risk compared to other anti-obesity medications. However, because this is an observational study, it does not prove causation. Patients with a history of suicidality were excluded, so this data does not apply to high-risk individuals. Consult your provider for personalized psychiatric risk assessment.
Tirzepatide was associated with a 48% lower risk of suicide ideation or attempts (aHR: 0.52, 95% CI: 0.28–0.91; P=0.001).
Why this rating
Observational real-world data with propensity score matching; strong association but explicitly noted as precluding definitive causality.
Source
Association of tirzepatide and the risk of suicide in a real-world cohort
Weichang Yu et al. · Frontiers in Psychiatry · 2025
DOI 10.3389/fpsyt.2025.1626103
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →